Effect of Combined Carbimazole and Curcuma longa Powder in Human Thyroid-Stimulating Hormone and Thyroperoxidase Antibody in Hyperthyroidism

Authors: Ahmed Abdi Hassan, Mustapha Muhammad Aliyu

Abstract:

Turmeric (Curcuma longa) belongs to the ginger family and is used for food coloring mostly in Asian countries. It has long traditional medicinal value for the treatment of inflammations with excellent antioxidant properties. The purpose of this study is to investigate the efficiency of turmeric powder in the treatment of hyperthyroidism when combined with carbimazole antithyroid drug. The trial was conducted on 20 hyperthyroid patients but only 16 of them were successfully enrolled for the study. The 16 patients were divided into two equal groups where one group was treated with the only carbimazole while the other group was treated with a combined approach of carbimazole plus turmeric for 6 months consecutively. The result obtained is promising showing an average improvement of 99% in Thyroid-stimulating hormone (TSH) and 88%Thyroid Autoantibodies (TPOAb) in patients treated with the combined approach compared to those treated with the only carbimazole with an average of 3% and 18% of TSH and TPOAb improvement respectively. However, no major difference has been observed in both T4 and T3. Therefore, turmeric powder is a promising treatment if carefully and consistently combined with carbimazole antithyroid drug at very low amounts of 1.5 to 2 grams for at least 2 to 3 times a week.

Keywords: Thyroid, curcuminoids, turmeric, thyroxine, triiodothyronine, thyroid stimulating hormone, TPOAb.

References:

[1] A. Maniakas, L. Davies, and M. E. Zafereo, “Thyroid disease around the world,” Otolaryngologic Clinics of North America, vol. 51, no. 3, pp. 631–642, 2018.
[2] A. P. Weetman, “Autoimmune thyroid disease,” Autoimmunity, vol. 37, no. 4, pp. 337–340, 2004.
[3] P. M. Osuna, M. Udovcic, and M. D. Sharma, “Hyperthyroidism and the heart,” Methodist DeBakey cardiovascular journal, vol. 13, no. 2, p. 60, 2017.
[4] X. Zeng, Y. Yuan, T. Wu, L. Yan, and H. Su, “Chinese herbal medicines for hyperthyroidism,” Cochrane Database of Systematic Reviews, no. 2, 2007.
[5] D. Zimmerman, “Fetal and neonatal hyperthyroidism,” Thyroid, vol. 9, no. 7, pp. 727–733, 1999.
[6] R. Ahmed, “Hyperthyroidism and developmental dysfunction,” Arch Med, vol. 9, no. 4, p. 6, 2017.
[7] I. Kravets, “Hyperthyroidism: diagnosis and treatment,” American family physician, vol. 93, no. 5, pp. 363–370, 2016.
[8] P. N. Taylor, D. Albrecht, A. Scholz, G. Gutierrez-Buey, J. H. Lazarus, C. M. Dayan, and O. E. Okosieme, “Global epidemiology of hyperthyroidism and hypothyroidism,” Nature Reviews Endocrinology, vol. 14, no. 5, p. 301, 2018.
[9] M. Khazan, M. Hedayati, S. Askari, and F. Azizi, “Adulteration of products sold as chinese herbal medicines for weight loss with thyroid hormones and pcp,” Journal of Herbal Medicine, vol. 3, no. 1, pp. 39–43, 2013.
[10] D. S. Ross, H. B. Burch, D. S. Cooper, M. C. Greenlee, P. Laurberg, A. L. Maia, S. A. Rivkees, M. Samuels, J. A. Sosa, M. N. Stan et al., “2016 american thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis,” Thyroid, vol. 26, no. 10, pp. 1343–1421, 2016.
[11] M. Søgaard, D. K. Farkas, V. Ehrenstein, J. Jørgensen, O. M. Dekkers, and H. T. Sørensen, “Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study.” European journal of endocrinology, vol. 174, no. 4, p. 409, 2016.
[12] D. El Khoury, R. Matar, and T. Touma, “Curcumin and endometrial carcinoma: an old spice as a novel agent,” International journal of women’s health, vol. 11, p. 249, 2019.
[13] P. Rathaur, W. Raja, P. Ramteke, and S. A. John, “Turmeric: The golden spice of life,” International Journal of pharmaceutical sciences and research, vol. 3, no. 8, p. 1987, 2012.
[14] A. C. P. Reddy and B. Lokesh, “Effect of dietary turmeric (curcuma longa) on iron-induced lipid peroxidation in the rat liver,” Food and chemical toxicology, vol. 32, no. 3, pp. 279–283, 1994.
[15] D. Ramadas and L. Srinivas, “Antioxidant effects of 28 kda antioxidant protein from turmeric (curcuma longa l),” Asian Journal of Pharmaceutical and Clinical Research, vol. 4, no. 1, pp. 75–79, 2011.
[16] M. C. Fadus, C. Lau, J. Bikhchandani, and H. T. Lynch, “Curcumin: An age-old anti-inflammatory and anti-neoplastic agent,” Journal of traditional and complementary medicine, vol. 7, no. 3, pp. 339–346, 2017.
[17] A. Siviero, E. Gallo, V. Maggini, L. Gori, A. Mugelli, F. Firenzuoli, and A. Vannacci, “Curcumin, a golden spice with a low bioavailability,” Journal of Herbal Medicine, vol. 5, no. 2, pp. 57–70, 2015.
[18] H. Mirzaei, A. Masoudifar, A. Sahebkar, N. Zare, J. Sadri Nahand, B. Rashidi, E. Mehrabian, M. Mohammadi, H. R. Mirzaei, and M. R. Jaafari, “Microrna: A novel target of curcumin in cancer therapy,” Journal of Cellular Physiology, vol. 233, no. 4, pp. 3004–3015, 2018.
[19] P. Basnet and N. Skalko-Basnet, “Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment,” Molecules, vol. 16, no. 6, pp. 4567–4598, 2011.
[20] C. Sharma, “Curcumin: A multifaceted herbal medicine,” International Journal of Herbal Medicine, vol. 7, pp. 52–58, 2019.
[21] A. C. P. Reddy and B. Lokesh, “Studies on spice principles as antioxidants in the inhibition of lipid peroxidation of rat liver microsomes,” Molecular and cellular biochemistry, vol. 111, no. 1-2, pp. 117–124, 1992.
[22] G. SHARMA and N. THAKUR, “Curcumin–the healing herb: Properties and future prospective,” Asian J Pharm Clin Res, vol. 13, no. 2, pp. 4–9, 2020.
[23] M. R. Hamblin, “Shining light on the head: photobiomodulation for brain disorders,” BBA clinical, vol. 6, pp. 113–124, 2016.
[24] A. Tamaddoni, E. Nasseri, E. Mohammadi, D. Qujeq, F. Zayeri, H. Zand, S. M. Mir, and M. Gholami, “A double-blind randomized controlled trial of curcumin for improvement in glycemic status, lipid profile and systemic inflammation in β-thalassemia major,” Journal of Herbal Medicine, p. 100324, 2019.
[25] S. J. Hewlings and S. Douglas, “Kalman. 2017.“,” Curcumin: A Review of Its’ Effects on Human Health.” Foods, vol. 6, pp. 10–92, 2017.
[26] N. Ahmadi Nasab, H. Hassani Kumleh, M. Beygzadeh, S. Teimourian, and M. Kazemzad, “Delivery of curcumin by a ph-responsive chitosan mesoporous silica nanoparticles for cancer treatment,” Artificial cells, nanomedicine, and biotechnology, vol. 46, no. 1, pp. 75–81, 2018.
[27] M. Luisa, M. Emma, C. Botto, G. Augello, A. Azzolina, F. Di Gaudio, E. Craparo, G. Cavallaro, and D. Bachvarov, “Biocompatible lipid nanoparticles as carriers to improve curcumin,” Journal of Agricultural and Food Chemistry, vol. 65, pp. 1342–1352, 2017.
[28] N. Gittoes and J. Franklyn, “Hyperthyroidism. current treatment guidelines.” Drugs, vol. 55, no. 4, p. 543, 1998.
[29] S. K. Grebe, C. M. Feek, H. C. Ford, J. N. Fagerstr¨om, D. P. Cordwell, J. W. Delahunt, and R. J. Toomath, “A randomized trial of short-term treatment of graves’ disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole,” Clinical endocrinology, vol. 48, no. 5, pp. 585–592, 1998.
[30] D. J. Toft, “Radioactive iodine therapy for hyperthyroidism is associated with increased solid cancer mortality,” Clinical Thyroidology, vol. 31, no. 8, pp. 326–329, 2019.
[31] O. A. Uduak, E. J. Ani, E. C. I. Etoh, and A. O. Macstephen, “Comparative effect of citrus sinensis and carbimazole on serum t4, t3 and tsh levels,” Nigerian medical journal: journal of the Nigeria Medical Association, vol. 55, no. 3, p. 230, 2014.
[32] E. H. Gan, A. L. Mitchell, R. Plummer, S. Pearce, and P. Perros, “Tremelimumab-induced graves hyperthyroidism,” European thyroid journal, vol. 6, no. 3, pp. 167–170, 2017.
[33] R. Le Moli, P. Malandrino, M. Russo, F. L. Giudice, F. Frasca, A. Belfiore, and R. Vigneri, “Corticosteroid pulse therapy for graves’ ophthalmopathy reduces the relapse rate of graves’ hyperthyroidism,” Frontiers in Endocrinology, vol. 11, 2020.
[34] J. H. Mestman, “Hyperthyroidism in pregnancy,” Endocrinology and metabolism clinics of North America, vol. 27, no. 1, pp. 127–149, 1998.
[35] M. S. Zaman, N. Chauhan, M. M. Yallapu, R. K. Gara, D. M. Maher, S. Kumari, M. Sikander, S. Khan, N. Zafar, M. Jaggi et al., “Curcumin nanoformulation for cervical cancer treatment,” Scientific reports, vol. 6, p. 20051, 2016.
[36] E. Jayashree and T. J. Zachariah, “Processing of turmeric (curcuma longa) by different curing methods and its effect on quality,” Indian Journal of Agricultural Sciences, vol. 86, no. 5, pp. 136–139, 2016.
[37] K. P. Nair, “Turmeric in ayurveda,” in Turmeric (Curcuma longa L.) and Ginger (Zingiber officinale Rosc.)-World’s Invaluable Medicinal Spices. Springer, 2019, pp. 235–243.
[38] J. Henderson, L. Portmann, G. Van Melle, E. Haller, and J. Ghika, “Propranolol as an adjunct therapy for hyperthyroid tremor,” European neurology, vol. 37, no. 3, pp. 182–185, 1997.
[39] J.-L. W´emeau, P. Caron, C. Schvartz, J.-L. Schlienger, J. Orgiazzi, C. Cousty, V. Vlaeminck-Guillem, and F. T. R. Group, “Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo-controlled trial by the french thyroid research group,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 11, pp. 4928–4934, 2002.
[40] C. Spencer, J. Hollowell, M. Kazarosyan, and L. Braverman, “National health and nutrition examination survey iii thyroid-stimulating hormone (tsh)-thyroperoxidase antibody relationships demonstrate that tsh upper reference limits may be skewed by occult thyroid dysfunction,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 11, pp. 4236–4240, 2007.
[41] R. H. Lee, C. A. Spencer, M. N. Montoro, P. Aghajanian, T. M. Goodwin, E. A. Miller, I. Petrovic, L. E. Braverman, and J. H. Mestman, “Effect of thyroid peroxidase antibodies on thyroid-stimulating hormone reference limits in a primarily latina population,” Obstetric medicine, vol. 2, no. 4, pp. 154–156, 2009.